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Stromal cells in spleen organize tissue into red pulp, white pulp and marginal zone, and
also interact with hematopoietic cells to regulate immune responses. This study has
used phenotypic information of a previously described spleen stromal cell line called
5G3, which supports restricted hematopoiesis in vitro, to identify an equivalent stromal
cell subset in vivo and to test its capacity to support hematopoiesis. Using stromal cell
fractionation, phenotypic analysis, as well as cell growth and hematopoietic support
assays, the Sca-1+gp38+Thy1.2+CD29+CD51+ fraction of spleen stroma has been
identified as an equivalent stromal subset resembling the 5G3 cell counterpart. While
heterogeneity may still exist within that subset, it has been shown to have superior
hematopoietic support capacity compared with the 5G3 cell line, and all other spleen
stromal cell fractions tested.
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INTRODUCTION
Stromal cells of mesenchymal lineage represent a supporting cellular network forming the basement
layer in tissue and contributing to organ architecture and function (Mueller and Germain, 2009;
Roozendaal and Mebius, 2011). In the case of spleen, distinct stromal cells are identifiable in the
regions of red pulp, white pulp and marginal zone. So far, several distinct mesenchymal stromal cell
types have been described in spleen. Splenic fibroblastic reticular cells assist in regulating immune
responses through secretion of chemokines like CCL19 and CCL21 (Luther et al., 2000). Others
include gp38+ fibroblastic reticular cells, MadCAM1+ marginal reticular cells, CD35+ follicular
dendritic cells, CD105+ red pulp fibroblasts and CD31+ vascular endothelial cells (Mueller and
Germain, 2009; den Haan et al., 2012).
Many studies have investigated the function of splenic stroma in immune regulation (Malhotra
et al., 2013), but limited studies have addressed their hematopoietic support capacity. The
perception in the field is that extramedullary hematopoiesis occurs in spleen with stress or disease.
However, questions remain about the role of spleen in steady-state hematopoiesis (Kim, 2010; Johns
and Christopher, 2012). A role for spleen in hematopoiesis has been clearly defined in mice, and
several studies now indicate the presence of hematopoietic stem cells (HSC) in spleen of several
species including humans (Dor et al., 2006; Tan and O’Neill, 2010; Inra et al., 2015). Definition of
a role for spleen in hematopoiesis would offer tremendous clinical potential, and the substantial
knowledge of bone marrow hematopoiesis could easily be directed to a study of hematopoiesis
in spleen. Furthermore, there has been no in-depth analysis of splenic stroma which could be
candidate elements for HSC niches.
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Previously, we described a cloned stromal cell line called 5G3
which is unique in its ability to support in vitro hematopoiesis.
When 5G3 stroma was overlaid with bone marrow progenitors,
transient production of myeloid and conventional dendritic-like
cells (cDC) was reported, as well as the continuous production
of a specific dendritic-like cell called ‘L-DC’ (Periasamy et al.,
2009; Petvises and O’Neill, 2014a,b). The cDC-like cells were
recently identified as regulatory DC (Petvises et al., 2018). Several
studies also identified the maintenance of progenitors within co-
cultures (Tsuchiyama et al., 1995; Corselli et al., 2013; Petvises
and O’Neill, 2014a), and the ability to achieve L-DC production
through overlay of HSC or multipotential progenitors (MPP)
above stroma (Hinton et al., 2011; Petvises and O’Neill, 2014b).
Longterm stromal cocultures maintain HSPC and this has been
demonstrated through in vivo reconstitution assays (O’Neill et al.,
2014). The 5G3 splenic stromal line expresses mesenchymal
markers like CD140a, CD51, CD29, gp38, Thy1, Sca-1, and
CD105 (Lim et al., 2018). Attempts have been made here to isolate
an in vivo equivalent stromal cell subset to 5G3 and to compare its
hematopoietic support capacity with other stromal fractions. This
study uses marker analysis to define stromal subsets in spleen and
to assess their capacity for in vitro growth. It also identifies subsets
which support hematopoiesis which could represent candidate
niche elements for hematopoiesis in spleen. This in vivo study
therefore provides physiological relevance to studies describing
in vitro hematopoiesis.
MATERIALS AND METHODS
Animals
Specific pathogen-free C57BL/6J (H-2Kb: CD45.2) mice aged
6 days or 4–8 weeks were obtained from the John Curtin School
of Medical Research (JCSMR: Canberra, ACT, Australia). Mice
were housed and handled according to protocols approved by
the Animal Experimentation Ethics Committee at the Australian
National University (ANU: Canberra, ACT, Australia).
Cell Cultures
The 5G3 stroma was derived from the STX3 splenic stromal
line by single-cell cloning and freezing down (Despars and
O’Neill, 2006a,b; Despars et al., 2008). Cells were cultured at
37◦C in 5% CO2 in air with 95% humidity in supplemented
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich: Castle Hill,
NSW, Australia) containing 10% fetal calf serum, 5 × 10−4 M 2-
mercaptoethanol, 10 mM HEPES, 100 U/ml penicillin, 100 µg/ml
streptomycin, 4 mg/L glucose, 6 mg/L folic acid, 36 mg/L L-
asparagine, 116mg/l L-asparagine hydrochloric acid (sDMEM).
Stromal cells were passaged twice by transferring scraped cells
into new flasks before use in experiments.
Fractionation of Bone Marrow
Progenitors
Methods for isolation of bone marrow progenitors have been
described (Periasamy et al., 2013; Petvises and O’Neill, 2014a).
Bone marrow cells were flushed from femurs of C57BL/6J adult
mice. Red blood cells were selectively lysed using lysis buffer.
MACS R© magnetic bead technology (Miltenyi Biotec: Gladbach,
Germany) was used to deplete lineage-specific hematopoietic
cells. The process involved labeling cells with a cocktail of lineage-
specific biotinylated antibodies with specificity for NK1.1,
CD11b, CD11c, Gr-1, MHC-II, Ter119, CD3 and CD19, followed
by anti-biotin microbeads, which were captured in LS or MS
columns (Miltenyi Biotec). Lin− bone marrow progenitors were
eluted and collected.
Dissociation of Splenic Stromal Cells
Murine adult or 6 day old spleens were dissociated by pressing
between microscope slides before filtering through a 70 µm
strainer. The stromal fraction was collected in a tube containing
2 ml collagenase IV extraction buffer [(2% fetal calf serum,
1 mg/ml collagenase IV (Sigma-Aldrich) and 40 µg/ml DNase
I (Sigma-Aldrich) in RPMI] and incubated for 20 min at 37◦C
with rotation. Two ml collagenase D extraction buffer [2% fetal
calf serum, 1 mg/ml collagenase D (Roche Applied Science: North
Ryde, NSW, Australia) and 40 µg/ml DNase I in RPMI] was
added for another 20 min incubation at 37◦C with rotation. An
additional 2 ml of collagenase D extraction buffer was added and
the cell suspension incubated for 20 min at 37◦C with rotation.
The activity of collagenase was halted by addition of 60 µL of
500 mM EDTA to give a final concentration of 5 mM. Digested
spleens were washed twice with 5 ml sDMEM (300 g, 4◦C, 5 min),
and viable cell count determined using trypan blue staining. The
cell pellet was resuspended in 1ml sDMEM for antibody staining,
flow cytometric analysis and sorting.
Antibody Staining and Flow Cytometric
Analysis
The procedures used to stain cells and assess antibody binding
have been described (Periasamy et al., 2009; Periasamy and
O’Neill, 2013; Petvises and O’Neill, 2014b). Antibodies used
were specific for CD11b (clone M1/70), CD11c (N418),
NK1.1 (PK136), Gr-1 (RM6-8C5), Ter119 (TER119), CD3
(145-2C11), CD19 (6D5), c-Kit (2B8), FLT3 (A2F10), CD150
(TC15-12F12.2), MHC-II (AF6-120.1), F4/80 (BM8), CD45.2
(104), CD29 (HMβ1-1), CD51 (RMV-7), CD54 (YN1/1.7.4),
CD31 (390), gp38 (8.1.1), CD105 (MJ7/18), Thy1.2 (30-
H12), VCAM1 (429), CD140a (APA5), CD146 (ME-9F1),
Sca-1 (D7), ER-TR7 (Sc-73355), MAdCAM1 (MECA-367).
Conjugates included streptavidin-Alexa780, streptavidin-APC-
Cy7, streptavidin-PE, and streptavidin-FITC. Antibodies and
conjugates were purchased from Biolegend (San Diego, CA,
United States) or eBiosciences (Parkville, Victoria, Australia).
Fluorescence minus one (FMO) controls or isotype controls
were used to set gates to delineate specific antibody binding.
Discrimination of dead cells was carried out following staining
with 1 µg/ml propidium iodide (PI). Flow cytometric analysis
and sorting utilized either a FACSDiva or a LSRII flow cytometer
(Becton Dickinson: Franklin Lakes, NJ, United States). Post-
acquisition analysis was carried out using FlowJo software (Tree
Star: Ashland, OR, United States). For isolation of stromal
subsets, cells were sorted into FACS buffer without added sodium
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azide, washed twice with phosphate buffered saline (Sigma-
Aldrich), and plated for in vitro growth analysis. Sorted cells
were re-analyzed flow cytometrically to ensure that purity of
the sort was >99%. For sorting HSC, Lin− bone marrow
progenitors were prepared and stained with fluorochrome-
conjugated antibodies to lineage markers, as well as specific
markers. The longterm (LT)-HSC subset was isolated as Lin−Sca-
1+c-Kit+Flt3−CD150+ cells (Kiel et al., 2005).
Culture of Stromal Fractions
Stromal cells sorted by flow cytometry were cultured (5% CO2
in air with 95% humidity at 37◦C) in a 6-well plate containing
sDMEM for 28 days or until about 90% confluent. Cells were
passaged from 6-well plates into a 25 cm2 flask and maintained
until 90% confluency was obtained. Cells underwent a second
passage from 25 cm2 into 75 cm2 flasks. Cells in the 75 cm2 flasks
were either analyzed for cell surface marker expression using
flow cytometry, or tested for hematopoietic support capacity in
co-culture assays.
Stromal Co-cultures
In order to assess hematopoietic support capacity of stroma, Lin−
bone marrow cells were prepared as above and overlaid at 1–
5 × 104 cells/ml in 20 ml sDMEM above stromal monolayers of
80–90% confluency. In some experiments, HSC were overlaid at
1–5 × 102 cells/ml in 5 ml sDMEM above stroma. Co-cultures
were kept at 37◦C, 5% CO2 in air and 97% humidity. Production
of cells in co-cultures was monitored over a period of 4–6 weeks
using flow cytometry and light microscopy. Since co-cultures
established at different times varied in cell yield over the course
of culture, each test of hematopoietic support capacity included
5G3 stroma as a control. At 7-day intervals, non-adherent cells
were collected by aspiration and replacement of medium. Trypan
blue exclusion was used to determine cell yield. Cells were then
resuspended in FACS buffer for flow cytometry, in order to
detect cell surface marker expression and to define and quantitate
subsets.
Gene Expression Analysis
Gene expression was measured by quantitative real time
polymerase chain reaction (qRT-PCR). Total RNA was isolated
from stromal cell lines using the RNeasy mini kit and the
manufacturer’s protocol (Qiagen, SABiosciences: Valencia, CA,
United States). Genomic DNA elimination mix was added to
400–600 µg of RNA followed by incubation for 5 min at 42◦C
to purify RNA. Following this, Buffer BC3, Control P2, Reverse
Transcriptase mix and RNase-free water were added in ratios
of 4:1:2:3 for preparation of cDNA. Denaturation proceeded
for 15 min at 42◦C, then for 5 min at 95◦C to convert RNA
into cDNA. Equal volumes of cDNA and primer were mixed.
Primers were purchased from SABioscience (Frederick, MD,
United States: Scf : PPM02983C; Cxcl12: PPM02965E; Actb:
PPM02945A). The cDNA/primer mix was then added to the
RT2 SYBR Green Mastermix and RNase-free water in a ratio of
1:6.25:5.25, respectively. Samples were loaded on to a LightCycler
480 (Roche: Penzberg, BAV, Germany) with cycling conditions:
1 cycle for 10 min at 95◦C to activate DNA Taq Polymerase,
followed by 45 cycles of 15 s at 95◦C for extension, and
then 1 min at 60◦C for fluorescence data collection. Roche
LightCycler 480 software v.11.2.9.11 was used to analyze qRT-
PCR data. Derivation of crossing point (Cp) was carried out
using the absolute quantification (2nd derivative max) method
at high confidence. Cp is defined as the point at which the
maximal increase in fluorescence occurs within the log-linear
phase. The Cp value is also referred to as threshold cycle
(Ct). 1Ct = Ct (Gi) − Ct(Gr), where Gi refers to gene of
interest and Gr refers to reference gene. Fold change relative
to β-actin was expressed as 2−1Ct (gene of interest)/2−1Ct
(β-actin).
Microscopy
Cell morphology was observed and photographed using an
EVOS R© FL digital fluorescence microscope (Electron Microscope
Sciences: Hatfield, PA, United States), equipped with a Sony R©
ICX445 CCD camera (Sony: Minato, TKY, JP).
Statistical Analysis
Data are presented as mean± standard error (SE) for sample size
n. The Student’s t-test was used to assess significance (p ≤ 0.05).
RESULTS
Composition of Splenic Stroma
In order to investigate the stromal cell composition of murine
spleens, collagenase-dissociated stromal cells were fractionated
using flow cytometry to enrich or deplete subsets expressing a
particular marker(s). Previously 6 day old spleens were found to
give optimal production of longterm stroma-dependent cultures
supporting hematopoiesis, although other ages could be used
but with less effectiveness. For this reason, 6 day old mice
were used for characterization of splenic stromal subsets. The
initial choice of markers was based on the phenotype of the
TABLE 1 | Proportion of cells in CD45− stromal fractions.
Spleen fractiona % cellsb
CD29+ 91.70 ± 2.70
Sca-1+ 1.57 ± 0.50
CD31+ 1.02 ± 0.23
gp38+ 0.99 ± 0.32
CD105+ 13.07 ± 1.26
CD140a+ 1.76 ± 0.67
CD51+ 1.64 ± 0.73
ER-TR7+ 2.12 ± 0.67
Thy1.2+ 0.32 ± 0.11
CD146+ 1.33 ± 0.36
MAdCAM1+ 0.35 ± 0.06
VCAM1+ 6.82 ± 3.60
aStromal cells were isolated from neonatal murine spleen using collagenase
treatment. Cells were labeled with fluorochrome-conjugated antibodies and flow
cytometry used to separate marker-positive and marker-negative fractions for
quantification. bData represent mean ± SE (n = 3).
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TABLE 2 | Phenotype of stromal fractions after culture.
Cell fractionsa,b Growthc Phenotype of 28 day stromad
Sca1 gp38 CD51 CD105 ERTR7 CD140a Thy1.2
Endothelial cell markers
CD31+ (n = 1) −
CD31− (n = 1) ∗∗ ++ + +++ − − + +
VCAM1+ (n = 1) −
VCAM1− (n = 1) ∗ +++ +++ +++ +++ − − +++
PVRC markers
CD146+ (n = 4) −
CD146− (n = 4) −
MadCAM1+ (n = 3) −
MAdCAM1− (n = 3) −
Common stromal markers
Sca-1+ (n = 3) ∗ +++ ++ +++ + − − +++
Sca-1− (n = 3) ∗ +++ ++ +++ + − − ++
CD51+ (n = 1) ∗ +++ +++ +++ + − + +++
CD51− (n = 1) ∗ +++ +++ +++ ++ − − +++
ER-TR7+ (n = 2) ∗ +++ ++ +++ − − − +++
ER-TR7− (n = 2) ∗ +++ +++ ++ +++ − − −
aStromal cells were isolated from murine spleen using collagenase treatment and stained with antibodies specific for CD45.2 to gate out hematopoietic cells. They were
then stained for known markers of endothelial cells (CD31 and VCAM), perivascular reticular cells (PVRC) (CD146, MadCAM1) or common stromal cell markers (Sca-1,
CD51 and ER-TR7) to gate distinct fractions. Where indicated, replicate independent sorting experiments were conducted (n). Sorted subsets were cultured in sDMEM
for 28 days. b1–3 × 104 cells were plated, except for the MadCAM1+ subset where ∼3.4 × 103 cells were available for plating. cCell growth: confluent by 10 days (∗∗),
confluent by 28 days (∗), no confluence (−). dCells were trypsinised and stained with antibodies to determine phenotype. +++, >80% cells expressing; ++, 50–80%; +,
10–50%; −, <10%.
TABLE 3 | Further phenotyping of stromal fractions after culture.
Cell fractionsa,b Growthc Phenotype of 28 day stromad
Sca1 gp38 CD51 CD105 ERTR7 CD140a Thy1.2
CD29+ (n = 2) ∗∗ +++ +++ +++ +++ − + +++
CD29− (n = 2) X
gp38+ (n = 5) ∗ +++ +++ ++ ++ − ++ ++
gp38− (n = 5) −
CD105+ (n = 5) ∗ +++ +++ ++ +++ − + ++
CD105− (n = 5) −
CD140a+ (n = 5) ∗ ++ +++ ++ − − − ++
CD140a− (n = 5) −
Thy1.2+ (n = 3) ∗ ++ + + + − ++ +++
Thy1.2− (n = 3) X
aStromal cells were isolated from murine spleen using collagenase treatment and stained with antibodies specific for CD45.2 to gate out hematopoietic cells. They were
then stained for either CD29, gp38, CD105, CD140 or Thy1.2 which distinguished subsets which grew well in vitro. Independent, replicated sorting experiments were
conducted to confirm results (n). Sorted cell subsets were cultured in sDMEM for 28 days. b1–3 × 104 cells were plated, except for the more prevalent CD29+ cells,
where 1.6 × 106 cells were plated. cCell growth: confluent by 10 days (∗∗), confluent by 28 days (∗), no confluence (−), and no growth (X). dCells were trypsinised and
stained with antibodies to determine phenotype. +++, >80% cells expressing; ++, 50–80%; +, 10–50%; −, <10%.
5G3 line, as well as knowledge of mesenchymal cells. A high
proportion of splenic stromal cells (91.70 ± 4.05%) was found
to express CD29 (integrin beta-1) (Table 1). In contrast, markers
like Sca-1, CD31, gp38, CD140a, CD51, ER-TR7, Thy1.2, CD146,
MadCAM1 and VCAM1 were expressed by minority populations
of stroma (1–3%) (Table 1). CD105+ cells represented ∼13%
of stromal cells in spleen, with VCAM1+ ∼7%. Splenic stromal
cell characterization was therefore challenging, requiring analysis
and isolation of rare stromal cells expressing markers of
interest.
In developing a strategy for detection of stromal subsets which
support hematopoiesis, we were cognizant of the fact that the
5G3 phenotype may not accurately reflect the stromal cell from
which 5G3 derived. We therefore performed a systematic study
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of marker defined stromal fractions to eliminate subsets which
did not grow, and which did not support hematopoiesis. An
important criterion was the capacity of the stromal fraction to
grow to confluency within 28 days in order to test hematopoietic
support capacity. This approach precluded multicolor sorting
yielding very small numbers of cells which could not form a
monolayer in vitro.
In a first experiment, marker identity of fractions which grew
in vitro was determined by comparing growth capacity of subsets
enriched or depleted of cells expressing a given marker. Markers
were considered unimportant when the same growth capacity
was achieved for depleted and enriched fractions (either did
or did not grow), and where depletion and not enrichment
gave a growing population. Depletion of stroma expressing
the endothelial markers CD31 and VCAM1 gave a stromal
population which grew readily, so these markers were removed
from consideration (Table 2). Stromal cells enriched or depleted
for CD146 and MadCAM, known markers of niche elements
in bone marrow, did not grow despite multiple replicated
experiments (Table 2). This could be due to inability to isolate
enough cells, or their inherent inability to form a monolayer,
so these markers were eliminated from further consideration.
The more common stromal cell markers Sca-1, CD51 and
ERTR7, were not deterministic of growth since both depleted
and enriched subsets grew (Table 2). This initial screen led to
the identification of CD29, gp38, CD105, CD140a and Thy1
as deterministic markers. Only fractions enriched for, but not
depleted of CD29, gp38, CD105, Thy1.2 and CD140a, could
reach confluent growth by 28 days (Table 3). These mesenchymal
markers would appear to identify stromal cells that can replicate
in culture. Subsets expressing these markers were therefore tested
for hematopoietic support capacity.
Cells which grew out of 28-day cultures were also
mesenchymal in terms of phenotype (Tables 2, 3). For all
stromal fractions tested, cells which grew expressed Sca-1
(50–80% of cells), with a majority of cells also expressing gp38,
CD51 and Thy1.2 (50–80%). The expression of CD105 was
variable, with some cultures showing no expression. CD140a
FIGURE 1 | Morphology of splenic stromal fractions. Stromal cells were isolated from murine spleen using collagenase treatment, stained with antibody and sorted
flow cytometrically. Cells were cultured and photographed after 28 days using a camera attached to an inverted phase microscope. Stromal fractions sorted on the
basis of a single marker were tested for in vitro growth. (A) CD29+, (B) Sca-1+, (C) CD140a+, (D) CD105+, (E) gp38+, (F) ERTR7+, (G) CD51+ and (H) Thy1.2+.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 January 2019 | Volume 7 | Article 1
fcell-07-00001 January 22, 2019 Time: 16:46 # 6
Lim and O’Neill Mesenchymal Stroma in Spleen
expression was also weak and variable with between 0 and 50%
of cells expressing this marker. None of the cultures showed
expression of the fibroblastic marker ER-TR7. These data need to
be interpreted with caution since in vitro growth can moderate
or enhance expression of markers. In sum, a small number of
lines of distinct mesenchymal type can be cultured, showing
variability in expression of CD105 and CD140a.
Microscopic Examination of Cultured
Stromal Fractions
Most stromal monolayers were heterogeneous showing a mix
of spindle-shaped fibroblastic and cuboidal cells. The extent
of confluency achieved for different fractions varied even after
28 days of culture. Enrichment of CD29+, Sca1+, CD140a+,
CD105+, gp38+, CD51+ and to a lesser extent Thy1.2+ cells,
gave confluent, extensive monolayers comprising mainly spindle-
shaped cells, reflective of mesenchymal stroma (Figure 1).
Enrichment for CD29+ cells gave a very mixed population
of cuboidal and spindle-shaped cells, consistent with CD29
as a marker of ∼90% of stromal cells in spleen (Table 1).
The extensive heterogeneity within the CD29+ fraction was
revealed by culturing CD29-expressing cells as three independent
subcultures (A, B, and C) for 28 days. Stromal cells in each of
A, B, and C subcultures showed very different growth rates and
morphologies. Sub-culture A reflected spindle-shaped cells, sub-
culture B sparse cuboidal cells, and sub-culture C was a confluent
mixture of cell types (data not shown). The ER-TR7+ fibroblastic
population grew rapidly yielding fibroblastic cells (Figure 1).
Further Marker Characterization of
Stroma
Since CD29+ cells represented ∼90% of stroma, subfractions
were isolated on the basis of CD105, Sca-1 and gp38
expression, and compared for growth. In general, stromal
fractions that expressed either CD29 or gp38 grew well
(Supplementary Table S1). Again, the phenotype of stromal
cells which grew out of 28 days cultures was consistently
Sca-1+gp38+Thy1.2+CD29+CD51+, with variability in the
expression of CD105 and CD140a (Supplementary Table S1).
As a prelude to assessment of potential of subsets to support
hematopoiesis, qRT-PCR was used to measure expression of
Scf and Cxcl12 (Figure 2) which encode factors known to
regulate hematopoiesis in bone marrow (Sugiyama et al., 2006).
Recent work on spleen stroma has aligned Cxcl12 expression
with perivascular reticular cells, and Scf expression with both
endothelial and perivascular reticular cells in the red pulp of
murine spleen (Inra et al., 2015). The A, B, and C subcultures
derived from an isolate of CD29+ stromal cells were compared
with 5G3 stroma and with several sorted fractions of CD105+,
CD29+gp38+Sca-1− and CD29+gp38+Sca-1+ spleen stroma, to
measure gene expression relative to β-actin (Figure 2). Cxcl12
was highly expressed in all stroma, and each not significantly
different from 5G3 at p = 0.05. Scf was more weakly expressed,
not detectable in 3 subsets, and each not significantly different
from 5G3 at p = 0.05 level. The dominant expression of Cxcl12
and weak expression of Scf by stromal fractions is consistent with
FIGURE 2 | Expression of hematopoietic factors by spleen stromal fractions.
Gene expression in 5G3 stroma was compared with several sorted stromal
fractions of spleen using qRT-PCR. Data represent the mean ± SE of gene
expression measured as fold change relative to the Actb (b-actin)
housekeeping gene for four replicated samples. Expression of Cxcl12 and Scf
by all stromal fractions tested was not significantly different from 5G3
(p < 0.05).
perivascular reticular cells amongst the spleen stromal fractions
(Inra et al., 2015).
An explanation for the data achieved to date is that one or
a small number of stromal subsets exist in spleen which are
readily cultured in vitro. These are identifiable as a CD29+Sca-
1+Thy1+CD51+gp38+ population, and contain perivascular
reticular cells.
Assessment of Hematopoietic Support
Capacity of Stromal Fractions
To assess hematopoietic support capacity of stromal fractions,
confluent monolayers were grown for 28 days and used to
establish co-cultures by overlay of Lin− bone marrow cells from
CD45-allotype distinct mice. The production of progenitors,
myeloid cells and dendritic cells was measured at 21 days through
staining with a range of antibodies. The CD11b−CD11c− subset
was identified as ‘progenitors’ although this phenotype describes
a heterogeneous population of progenitors/precursors. Myeloid
cells were identified as CD11b+CD11c−F4/80−MHC-II−, L-DC
as CD11b+CD11c+F4/80+MHC-II− cells and regulatory DC
cells as CD11b+CD11c+F4/80+/−MHC-II+. Initial studies
involved stromal cell fractions separated by a single marker.
Eleven independent co-culture experiments were performed
to test various stromal fractions using 5G3 as a control.
Nine representative experiments show % yield of cells relative
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FIGURE 3 | In vitro hematopoietic support capacity of stromal cell fractions. Stromal fractions were isolated from collagenase treated spleen stroma, sorted on the
basis of marker expression and cultured for 28 days until confluent. Lin− bone marrow cells was then overlaid above stroma at 1–5 × 104 cells/ml in 20 ml.
Non-adherent cells were collected after 21 days and stained with antibodies to CD11b, CD11c, MHC-II and F4/80 to delineate myeloid/dendritic cell production.
Flow cytometric analysis was used to identify subsets of progenitors (CD11b−CD11c−), myeloid cells (CD11b+CD11c−F4/80−MHC-II−), L-DC
(CD11b+CD11c+F4/80+MHC− II−), and cDC-like cells (CD11b+/−CD11c+F4/80−MHC− II+). Multiple individual self-controlled experiments were conducted, each
comparing cell production by different fractions in comparison with 5G3. Data is shown for each of 9 experiments as: (A) % yield as number of cells produced
relative to input cell number, and (B) proportional representation of subsets.
to input cell number (Figure 3A). An example of the
flow cytometric gates used to identify cell subsets produced
in co-cultures is shown in Figure 4B and has also been
published previously (Lim et al., 2018). Most stromal fractions
were low cell producers compared with 5G3, including
CD105+, CD51+, gp38+, Sca-1+, Thy1.2+, CD29+CD105+,
CD29+B and CD29+C, ERTR7+, CD29+gp38−, CD140a+,
CD29+CD105− and CD45−CD31− stroma. Several stroma gave
yields equal to 5G3 including CD29+A, CD29+gp38+Sca-1+ and
CD29+gp38+Sca-1−. Co-cultures established using the CD29+
subcultures A, B, and C, exhibited different hematopoietic
support capacity, again reflective of the heterogeneity within
this stromal fraction (Figure 3A). Replication experiments
therefore involved independent sorts and growth of stromal
fractions for 4 weeks. For reasons of low subset size it
was not possible to perform replicate tests of hematopoiesis
for any one sorted stromal fraction. Since the independently
sorted and grown populations reflect distinct outgrowths of
a heterogeneous population as seen for subcultures of the
CD29+ fraction, it is not possible to determine with certainty
a measure of the hematopoietic support capacity for impure
stromal fractions. It was anticipated, however, that if a stromal
fraction could be defined on the basis of multiple markers
that it would be more likely to reflect a single stromal cell
population.
The phenotype of cells produced in co-cultures was found
to be similar across many stromal subsets analyzed across 11
different experiments (Figure 3B). Furthermore, after 21 days,
there was a predominance of L-DC produced in most co-cultures
with variable representation of myeloid cells and progenitors.
Only 5G3 co-cultures showed evidence of a small subset of
regulatory DC which are known to be transiently produced
(Periasamy et al., 2013). Initial experiments confirmed no
production of T or B lymphoid cells in any co-culture established
with spleen stroma or the 5G3 cell line, consistent with previous
reports (Periasamy et al., 2009; Petvises and O’Neill, 2014b),
and also with early studies on longterm stromal cultures of
spleen (O’Neill et al., 2004, 2014). Some stromal co-cultures
showed more extreme changes in cell production, most notably
subculture CD29+A which produced a high number of cells with
a predominant population of progenitors (Figure 3B).
Relative to the input number of Lin− bone marrow
progenitors, 5G3 co-cultures yielded a 2.034± 0.350 (mean± SE)
(n = 9) increase in cell number after 21 days (Figure 3A). This
fold change increase is more significant due to the fact that it
represents cell production measured at 21 days, and does not take
into account cells produced and lost at biweekly medium change.
The question of whether stromal co-cultures cause expansion or
maintenance of HSPC can be addressed as well. Nineteen of 20
co-cultures shown across 9 experiments in Figure 3 gave a yield
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FIGURE 4 | Splenic stroma supports hematopoietic progenitors. Stromal
fractions expressing gp38, Thy1 or CD140 along with the CD45− fraction
were sorted and cultured for 28 days until confluent. 5G3 stroma was used as
a control. Co-cultures were prepared as described in Figure 3 utilizing Lin−
bone marrow progenitors in (A) or sorted Lin−Sca-1+c-Kit+Flt3−CD150+
LT-HSC in (B). Cultures were trypsinised at cell harvest to ensure isolation of
any progenitors adherent to stroma before staining with antibodies to
delineate cell subsets. Fluorescence minus one (FMO) controls were used to
set gates. (A) Cells harvested at 35 days were stained for lineage (Lin)
markers and CD45.2, as well as c-Kit and Sca-1, to identify hematopoietic
progenitors. (B) Cells harvested at 28 days were stained for CD11b, CD11c,
MHC-II, and F4/80 to delineate myeloid/dendritic cell production: myeloid
cells (CD11b+CD11c−F4/80−MHC-II−), L-DC (CD11b+CD11c+/−F4/80+
MHC− II−), regulatory DC (CD11b+/−CD11c+F4/80−MHC− II+) and
progenitor-containing subset (CD11b−CD11c−).
of progenitors which was less than the input number of Lin−
bone marrow progenitors. However, CD29+A cultures gave a
2.7-fold increase in progenitors collected after 21 days compared
with input cell number (Figure 3B). This initial study confirmed
that spleen contains subsets of CD29+ cells which can support
the expansion of HSPC cells. Despite the low overall yield of
cells, gp38+ stromal co-cultures appear to maintain a higher
proportion of progenitors.
Stromal Cell Capacity to Maintain
Hematopoietic Progenitors
The question of whether stromal co-cultures can maintain
and expand hematopoietic stem and progenitor cells (HSPC)
in vitro has clinical importance. We therefore attempted to
identify HSC in several co-cultures established with freshly
prepared splenic stroma. Non-adherent cells collected from
co-cultures were stained to detect Lin−CD45.2+Sca-1+c-Kit+
HSPC. Only Lin−CD45.2+c-Kit+ cells could be detected in co-
cultures established above the CD45− and CD140a+ spleen
stroma fractions tested, and none in 5G3 co-cultures (Figure 4A).
These cells could reflect previously described common myeloid
progenitors (Akashi et al., 2000), myeloid/dendritic progenitors
(Fogg et al., 2006) or common dendritic progenitors (Liu et al.,
2009). Previously we reported that HSPC appear to be tightly
adhered to stroma so their isolation may not be easily achieved
(Wilson et al., 2000). It is also possible that HSC may be present,
but after for 3–4 weeks of culture, attain a different phenotype.
In particular, culturing of Lin−Sca-1+c-Kit+ cells over stroma
may lead to loss of the Sca-1 marker, a phenomenon reported
previously for mesenchymal stem cells in vitro (Deng et al., 2015).
Previously we reported evidence for maintenance of low numbers
of HSPC in spleen longterm stromal cultures through ability
to induce hematopoietic reconstitution in irradiated host mice
(O’Neill et al., 2014).
We showed previously that the 5G3 stromal cell line can
maintain bone marrow-derived HSC and MPP and support
hematopoiesis to give a mixed population of L-DC and
progenitors (Petvises and O’Neill, 2014b). Here we tested the
capacity of several ex vivo spleen stromal fractions to support
hematopoiesis in overlaid Lin−Sca-1+c-Kit+Flt3−CD150+ HSC.
When non-adherent cells were collected and stained for marker
expression, a substantial population of CD11b+CD11c+ cells was
detected for each of the gp38+ and Thy1+ stromal fractions as
well as for 5G3 (Figure 4B). These cells were further shown
to express F4/80 but not MHC-II consistent with production
of L-DC. A substantial CD11b−CD11c− subset was detectable
particularly for 5G3 cocultures (73%) while lower numbers of
progenitors were present in co-cultures of gp38+ (18.9%) and
Thy1+ (9.53%) stroma (Figure 4B). This subset is expected to
contain hematopoietic progenitors.
Fine Definition of Stromal Subsets in
Spleen
Further experiments were therefore aimed at identification of
subsets of more defined phenotype and hematopoietic support
capacity. Splenic stroma was characterized using five cell surface
markers to delineate subsets amongst the total ex vivo population.
The panel of markers comprised Thy1.2, Sca-1, CD105, CD51,
and CD140a, informed by the 5G3 phenotype and data obtained
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FIGURE 5 | Flow cytometric analysis of stromal subsets in spleen. Stromal cells were isolated from murine spleen using collagenase treatment and stained with
antibodies specific for CD45.2, Sca-1, Thy1.2, CD105, CD51 and CD140a. Prior to flow cytometry, cells were incubated with propidium iodide for gating live (PI−)
cells using PI versus SSC analysis. Singlets were then selected on the basis of FSC-H and FSC-A staining. Cells were then gated on FSC to eliminate red blood
cells. Multicolor analysis was then used to detect subsets amongst the CD45.2− population of non-hematopoietic stromal cells. Fluorescence minus one (FMO)
controls were used to set gates. Numbers in quadrants, or on circle gates, represent % specific binding. Distinct subsets were identified as P8, P9, P10, P11, P12,
and P13. Data reflect 3 independent experiments.
TABLE 4 | Characterization of specific subsets amongst the spleen stromal fraction.
(A) Subset representation.
Subseta Designationb % cellsc
Sca-1hiThy1.2−CD105+CD51loCD140a− P8 0.17 ± 0.068
Sca-1loThy1.2loCD105+CD51+CD140a+ P9 0.06 ± 0.021
Sca-1loThy1.2−CD105+CD51loCD140alo P10 0.52 ± 0.190
Sca-1loThy1.2−CD105−CD51+CD140alo P11 0.04 ± 0.006
Sca-1−Thy1.2loCD105loCD51+CD140alo P12 0.03 ± 0.007
Sca-1−Thy1.2−CD105+CD51+CD140alo P13 0.06 ± 0.017
(B) Phenotype of cells cultured out of stromal subsets.
Subsetb Cell number platedd Phenotype of 28 day stromae
P8 (2.8 ± 0.5).104 (n = 5) No growth
P9 (7.6 ± 1.5).103 (n = 5) Sca-1+gp38+CD51loCD105−CD29+ER-TR7−CD140a−Thy1.2+
P10 (9.8 ± 1.6).103 (n = 5) Sca-1+gp38+CD51−CD105−CD29+ER-TR7−CD140a−Thy1.2+
P11 (1.3 ± 9.6).102 (n = 5) No growth
aThe stromal the fraction of neonatal 6-day old spleen was isolated by collagenase digestion, stained for markers, and then delineated through flow cytometric gating of
CD45− cells. bSubset designation is shown in Figure 5. cData reflect mean ± SE (n = 3). dSubsets were cultured for 28 days to determine capacity to form a monolayer.
eMonolayers were trypsinised and cells stained with antibodies to determine phenotype flow cytometrically.
here on the growth and hematopoietic support function of
stromal fractions (Table 3 and Figure 3). Stromal cells were
prepared from 6 day old murine spleens using collagenase
treatment and stained for identification of subsets. Live (PI−),
non-hematopoietic (CD45.2−) stromal cells were first gated.
Further analysis showed three distinct populations based on
level of Sca-1 expression as Sca-1hi, Sca-1lo and Sca-1− cells
(Figure 5). These were subsequently analyzed for Thy1.2, CD105,
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TABLE 5 | In vitro hematopoietic support capacity of defined stromal subsets.
(A) Productivity of co-cultures established with stromal subsets.
Experimenta Test Control Relative yield in controlb Yield test/controlc
1 gp38+ 5G3 1.80 0.178
2 gp38+ 5G3 1.90 0.474
3 CD140a+ 5G3 2.68 0.119
4 CD140a+ 5G3 2.58 0.214
5 CD105+ 5G3 1.80 0.044
6 CD105+ 5G3 1.48 0.083
7 P10 5G3 1.90 7.11
8 P10 5G3 1.96 0.280
9 P9 5G3 1.48 3.71
10 P9 5G3 0.51 2.75
Mean ± SE 1.81 ± 0.18
aEach experiment involved two cocultures established by plating sorted test stroma and control stroma (5G3), with growth for 28 days to achieve near-confluent
monolayers. P9 and P10 reflect subsets described in Figure 5. A constant number of Lin− bone marrow cells (between 3.3 × 105 and 7 × 105) was then overlaid over
stroma and cultured for 21 days with complete removal of non-adherent cells weekly. Cell yield at 21 days was calculated. bCell production relative to input cell number
was constant for 5G3 co-cultures. cCell production in test versus control (5G3) co-cultures was calculated for each experiment. Values >1.0 are shown in bold.
(B) Proportion of myeloid subsets produced in stromal co-cultures.
% L-DCa,b % cDC-likea,b % Myeloida,b
1st Experiment 2nd Experiment 1st Experiment 2nd Experiment 1st Experiment 2nd Experiment
gp38+ 81.0 86.9 0.14 0 18.9 13.1
CD140a+ 75.1 65.6 0.08 0.03 24.8 34.3
CD105+ 87.9 39.3 0 0.02 12.2 60.5
P9 58.5 47.8 0.03 0 41.2 52.6
P10 52.4 47.8 0.01 0.04 47.6 52.1
5G3c 90.5 ± 1.77 2.63 ± 1.42 7.02 ± 0.41
aSee legend to table above. Data are shown for 2 independent experiments for test stroma. bFlow cytometry was used to identify myeloid cells produced in 21 day
co-cultures through staining with CD11b, CD11c, MHC-II and F4/80. Data shown represent proportion of subset relative to total myeloid subset defined as CD11c+
and/or CD11b+ cells. cData for 5G3 is shown as mean ± SE (n = 5).
CD51 and CD140a expression. The Sca-1hi subset contained a
single population (P8), while the Sca-1lo subset contained three
populations (P9, P10, and P11) (Figure 5). The Sca-1− subset
contained two populations of interest (P12 and P13) (Figure 5).
The proportional representation of these subsets amongst splenic
culture was measured in three replicate experiments. P10 was
the most predominant subset, although all were representative
of <1% of stromal cells in 6 day old spleens (Table 4). P9, P10,
and P11 reflect cells expressing marker profiles similar to 5G3.
Stromal subsets P8, P9, P10, and P11 were sorted from 6 day
old spleen for further study. Only P9 and P10 grew in vitro
and produced confluent stromal monolayers within 28 days.
These cells expressed a common Sca-1+gp38+CD29+Thy1.2+
phenotype, no longer expressing detectable levels of the CD105 or
CD140a markers used to isolate the starting population (Table 4).
Several stromal cell isolates including gp38+, CD140a+,
CD105+, P9 and P10 were sorted for direct comparison with 5G3
in terms of hematopoietic support capacity. Ten independent
experiments compared hematopoietic support capacity of a test
stroma in relation to 5G3 used as the internal control (Table 5).
Stromal cells were grown for 28 days to achieve minimal
confluence and then stromal monolayers were overlaid with
a constant number of Lin− bone marrow progenitors. Non-
adherent cells produced were removed weekly at medium change.
Cells removed at 21 days were assessed in terms of yield and
phenotype of cells produced. 5G3 showed reproducible capacity
to support hematopoiesis with an average (±SE) yield relative
to input cell number of 1.8.1 ± 0.18 across 10 experiments
(Table 5). Capacity of test stroma to produce hematopoietic
cells was then calculated relative to production in control co-
cultures. The gp38+, CD140a+ and CD105+ stromal fractions
gave yields less than that of 5G3 co-cultures, with CD105+
stroma being a very weak supporter. Two P9 co-cultures
gave cell yields 2.71× and 3.76× greater than 5G3 (Table 5).
Two P10 co-cultures gave distinctly different yields of 7.11×
versus 0.280×, perhaps reflecting the outgrowth of variant
stromal subsets as seen previously for CD29+ subpopulations
(Figure 3). When cells produced in stromal co-cultures were
assessed phenotypically, high numbers of L-DC and myeloid
cells were represented with very few cDC-like cells. Only
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5G3 produced cDC-like cells which were recently shown to
resemble regulatory DC (Petvises et al., 2018). Each of the
gp38+, CD140a+ and CD105+ stroma were high producers of
L-DC relative to myeloid cells resembling 5G3, although their
overall cell yield was lower than 5G3. Both P9 or P10 stroma
produced even numbers of L-DC and myeloid cells. All co-
cultures maintained a small population of CD11b−CD11c− cells
thought to contain myeloid progenitors and precursors (data not
shown).
DISCUSSION
Traditionally, the spleen is viewed as an immune organ
which also supports erythropoiesis (Mebius and Kraal, 2005;
Cesta, 2006). However, the spleen also plays an active role in
extramedullary hematopoiesis during times of stress, infection
and inflammation (Cesta, 2006; Johns and Christopher, 2012;
Yamamoto et al., 2016). In this study, we have studied steady-
state spleen to better understand the composition of stroma, its
heterogeneity and growth capacity with a view to assessing its
ability to support hematopoiesis. The hypothesis tested here is
that spleen contains perivascular reticular cells of mesenchymal
lineage which support hematopoiesis. Results confirm that the
spleen stromal population is highly heterogeneous, but contains
subsets which resemble mesenchymal perivascular cells which
secrete CXCL12 and SCF and can support hematopoiesis. Clearly
spleen contains a mixture of stromal cells of different phenotype
which serves to emphasize the complexity of the stromal network
and its important role in hematopoiesis and immune response
development. Previously this lab showed grafting of splenic
stromal cells sorted on the basis of a single marker (Tan and
Watanabe, 2014, 2018). Those grafts showed the presence of
hematopoietic cells and full development of splenic architecture.
Stromal subsets have been assessed for morphology,
phenotype, growth and hematopoietic support capacity. Stromal
fractions depleted of cells expressing CD29, gp38, CD105, Thy1.2
or CD140a failed to establish monolayers in culture, identifying
these as important markers of cells which can grow in vitro.
Stromal cells that grow out of 28-day cultures consistently show
a Sca-1+gp38+Thy1.2+CD29+CD51+ phenotype with some
variability in expression of CD105 and CD140a, indicative of
mesenchymal lineage cells readily expanded in vitro. However,
caution needs to be exercised in regard to marker expression,
since culturing conditions can lead to changes in surface maker
expression (Pevsner-Fischer et al., 2011).
The co-culture assay involving overlay of Lin− bone marrow
cells above 5G3 stroma has been extensively described (Periasamy
et al., 2009; Periasamy and O’Neill, 2013; Petvises and O’Neill,
2014b). Due to the low subset size of stromal fractions, and
the need to culture stroma for 4 weeks to obtain enough
cells for analysis of hematopoietic support capacity, it was
difficult to gain reproducible data on hematopoietic support
capacity for all stromal fractions. For this reason, a number
of complementary experiments were attempted to sort and
compare subsets of different marker phenotype. Overall the data
confirmed hematopoietic support capacity for subsets resembling
5G3 stroma, with production of L-DC, myeloid cells and very
few or no cDC-like cells in co-cultures. Exceptions were one
of the subcultures of CD29+ stroma, one P10 stromal culture
and the two P9 cultures. Stromal co-cultures also maintained
a small population of progenitor/precursor cells within the
CD11b−CD11c− subset.
Heterogeneity within splenic stromal subsets appears to
contribute to variability in hematopoietic support capacity and
this is very evident for P10 stroma. One out of 2 stromal cultures
of sorted P10 cells was a high cell producer. Given the relatively
large size of the P10 subset amongst the stromal subsets identified
in Table 4 and Figure 5, it is possible that P10 is heterogeneous,
and that further markers or single cell sequencing analysis will be
needed to identify stroma which are strong supporters amongst
this subset. In contrast, two isolates of the very small P9 subset
were very strong supporters of hematopoiesis. Data shown here
are consistent with a model whereby specific stromal cells,
perhaps defined by the P9 and P10 subsets identified here, have
superior hematopoietic support function.
The variability in hematopoietic support noted in this study
parallels that seen amongst clonal cell line derivatives of the
original parental STX3 splenic stromal line (Despars and O’Neill,
2006a; Periasamy et al., 2009). In that study, cloned stromal lines
derived from STX3, including 2A8, 5G3, and 10C9, were good but
variable supporters, whereas 3B5 was a much weaker supporter
(Periasamy et al., 2009). In this study, the equivalent in vivo
Sca-1+gp38+Thy1.2+CD29+CD51+ stromal cell subset has been
shown to grow in vitro and to support hematopoiesis. However,
since the markers which define this subset are not lineage-
specific, heterogeneity may still exist within this rare population.
Analyses of growth capacity have indicated the importance of
CD140a and CD105 as markers defining stromal subsets which
can grow in vitro and show hematopoietic support. However,
these were also found to be elusive markers showing variable and
sometimes weak expression, perhaps subject to in vitro growth
conditions.
While the main focus of the paper has been on identification
of stromal cells which reflect perivascular reticular cells
akin to those described in bone marrow, we have also
confirmed that some stromal fractions have capacity to
expand hematopoietic progenitors. We have so far been
unable to study these progenitors in detail due to the
small number of cells which can be collected from stromal
co-cultures. Future work will concentrate on the very
small P9 and P10 fractions and their capacity to support
hematopoiesis. Recent studies now describe splenic stromal
cells which act as niches for HSC under conditions of
extramedullary hematopoiesis (Inra et al., 2015; Oda et al.,
2018). However, these reports do not directly identify
stromal cells nor do they test their capacity for supporting
hematopoiesis. They are concerned with the contribution
of spleen to hematopoiesis under stress conditions, and
do not consider a role for spleen in hematopoiesis under
steady state conditions in normal animals. This study
contributes information on the stromal cell type which signals
hematopoiesis in the steady-state, as well the myeloid cell types
produced. The contribution of spleen to hematopoiesis is an
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important consideration particularly in regard to aging and HSC
transplantation in clinical settings.
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